{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T03:46:41Z","timestamp":1789616801792,"version":"build-2803163510"},"reference-count":97,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"am","delay-in-days":301,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Respiratory Investigation"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.resinv.2025.08.010","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T11:53:46Z","timestamp":1756468426000},"page":"1050-1059","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["The role of the coagulation-fibrinolysis system in airway and lung remodeling"],"prefix":"10.1016","volume":"63","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4141-0538","authenticated-orcid":false,"given":"Hajime","family":"Fujimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5748-1499","authenticated-orcid":false,"given":"Esteban C.","family":"Gabazza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.resinv.2025.08.010_bib1","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s44313-024-00040-8","article-title":"Back to basics: the coagulation pathway","volume":"59","author":"Park","year":"2024","journal-title":"Blood Research"},{"key":"10.1016\/j.resinv.2025.08.010_bib2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1161\/ATVBAHA.118.312130","article-title":"Intrinsic pathway of coagulation and thrombosis","volume":"39","author":"Grover","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.resinv.2025.08.010_bib3","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1055\/s-0040-1710013","article-title":"Role of factor XIa and plasma kallikrein in arterial and venous thrombosis","volume":"120","author":"Visser","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib4","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1111\/jth.13005","article-title":"Factor XI and contact activation as targets for antithrombotic therapy","volume":"13","author":"Gailani","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib5","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.blre.2014.09.003","article-title":"Fibrinolysis and the control of blood coagulation","volume":"29","author":"Chapina","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.resinv.2025.08.010_bib6","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1111\/jth.12950","article-title":"Reincarnation of ancient links between coagulation and complement","volume":"13","author":"Conway","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib7","doi-asserted-by":"crossref","first-page":"563","DOI":"10.2491\/jjsth.27.563","article-title":"The functional modules on thrombin molecule","volume":"27","author":"Suzuki","year":"2016","journal-title":"The Journal of Japanese Society on Thrombosis and Hemostasis"},{"key":"10.1016\/j.resinv.2025.08.010_bib8","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1172\/JCI22782","article-title":"The N-terminal domain of thrombomodulin sequesters high-mobility group-B1 protein, a novel anti-inflammatory mechanism","volume":"115","author":"Abeyama","year":"2005","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2025.08.010_bib9","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075961","article-title":"Recombinant thrombomodulin protects mice against histone-induced lethal thromboembolism","volume":"8","author":"Nakahara","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.resinv.2025.08.010_bib10","doi-asserted-by":"crossref","first-page":"3661","DOI":"10.1182\/blood-2008-03-142760","article-title":"Lectin-like domain of thrombomodulin binds to its specific ligand Lewis Y antigen and neutralizes lipopolysaccharide-induced inflammatory response","volume":"112","author":"Shi","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2025.08.010_bib11","first-page":"127","article-title":"Protein C anticoagulant system\u2014anti-inflammatory effects","volume":"34","author":"Charles","year":"2011","journal-title":"Semin Immunopathol"},{"key":"10.1016\/j.resinv.2025.08.010_bib12","doi-asserted-by":"crossref","first-page":"2381","DOI":"10.2741\/1977","article-title":"Protein C anticoagulant activity in relation to anti-inflammatory and anti-apoptotic activities","volume":"11","author":"Mosnier","year":"2006","journal-title":"Front Biosci"},{"key":"10.1016\/j.resinv.2025.08.010_bib13","doi-asserted-by":"crossref","first-page":"3161","DOI":"10.1182\/blood-2006-09-003004","article-title":"The cytoprotective protein C pathway","volume":"109","author":"Mosnier","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2025.08.010_bib14","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0021-9258(18)33235-6","article-title":"Protein C inhibitor: purification from human plasma and characterization","volume":"258","author":"Suzuki","year":"1983","journal-title":"J Biol Chem"},{"key":"10.1016\/j.resinv.2025.08.010_bib15","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/0896-6273(91)90167-X","article-title":"An extended family of protein-tyrosine kinase genes differentially expressed in the vertebrate nervous system","volume":"6","author":"Lai","year":"1991","journal-title":"Neuron"},{"key":"10.1016\/j.resinv.2025.08.010_bib16","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/nri2303","article-title":"Immunobiology of the TAM receptors","volume":"8","author":"Lemke","year":"2008","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.resinv.2025.08.010_bib17","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1126\/science.1061663","article-title":"Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family","volume":"293","author":"Lu","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.resinv.2025.08.010_bib18","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1182\/blood-2013-09-528752","article-title":"TAM receptors, Gas6, and protein S: roles in inflammation and hemostasis","volume":"123","author":"van \u2018t Veer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2025.08.010_bib19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/all.14261","article-title":"Protein S protects against allergic bronchial asthma by modulating Th1\/Th2 balance","volume":"75","author":"Asayama","year":"2020","journal-title":"Allergy"},{"key":"10.1016\/j.resinv.2025.08.010_bib20","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.3390\/ijms20051082","article-title":"Protein S is protective in acute lung injury by inhibiting cell apoptosis","volume":"20","author":"Baffour Tonto","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.resinv.2025.08.010_bib21","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1126\/science.101.2629.520","article-title":"Note on the absorption of thrombin on fibrin","volume":"101","author":"Seegers","year":"1945","journal-title":"Science"},{"key":"10.1016\/j.resinv.2025.08.010_bib22","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1055\/a-1910-4538","article-title":"Current view on the molecular mechanisms underlying fibrin(ogen)-dependent inflammation","volume":"122","author":"Yakovlev","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib23","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1159\/000321882","article-title":"The primary role of fibrinogen-related proteins in invertebrates is defense, not coagulation","volume":"3","author":"Hanington","year":"2011","journal-title":"J Innate Immun"},{"key":"10.1016\/j.resinv.2025.08.010_bib24","series-title":"Asthma","first-page":"35","article-title":"Epidemiologic trends","author":"Burney","year":"1997"},{"key":"10.1016\/j.resinv.2025.08.010_bib25","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1001\/archinte.1922.00110120002001","article-title":"The pathology of bronchial asthma","volume":"30","author":"Huber","year":"1922","journal-title":"Arch Int Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1164\/ajrccm.154.2.8756799","article-title":"Indices of airway inflammation in induced sputum: reproducibility and validity of cell and fluid-phase measurements","volume":"154","author":"Pizzichini","year":"1996","journal-title":"Am J Respir Crit Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/PL00007645","article-title":"Thrombin in the airways of asthmatic patients","volume":"177","author":"Gabazza","year":"1999","journal-title":"Lung"},{"key":"10.1016\/j.resinv.2025.08.010_bib28","first-page":"2550","article-title":"Increased local expression of coagulation factor X contributes to the fibrotic response in human and murine lung injury","volume":"119","author":"Scotton","year":"2009","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2025.08.010_bib29","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1164\/rccm.200608-1097OC","article-title":"Coagulation factor Xa modulates airway remodeling in a murine model of asthma","volume":"175","author":"Shinagawa","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib30","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1164\/rccm.200308-1156OC","article-title":"Increased thrombin activity after allergen challenge: a potential link to airway remodeling?","volume":"169","author":"Terada","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib31","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s004080000080","article-title":"Activation of protein C pathway in the airways","volume":"180","author":"Hataji","year":"2002","journal-title":"Lung"},{"key":"10.1016\/j.resinv.2025.08.010_bib32","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1172\/JCI200422288","article-title":"Coagulation-dependent mechanisms and asthma","volume":"114","author":"Matthay","year":"2004","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2025.08.010_bib33","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12014-022-09351-3","article-title":"Airway fibrin formation cascade in allergic asthma exacerbation: implications for inflammation and remodeling","volume":"19","author":"Zhu","year":"2022","journal-title":"Clin Proteom"},{"issue":"5","key":"10.1016\/j.resinv.2025.08.010_bib34","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4168\/aair.2015.7.5.421","article-title":"Chronic rhinosinusitis and the coagulation system","volume":"7","author":"Kim","year":"2015","journal-title":"Allergy Asthma Immunol Res"},{"key":"10.1016\/j.resinv.2025.08.010_bib35","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1136\/thx.2003.019588","article-title":"Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis","volume":"59","author":"Gan","year":"2004","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2025.08.010_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1055\/s-0037-1613998","article-title":"Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels","volume":"84","author":"Wedzicha","year":"2000","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib37","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1164\/ajrccm.164.6.2010067","article-title":"Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease","volume":"164","author":"Dahl","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib38","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1136\/thoraxjnl-2012-201871","article-title":"Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease","volume":"68","author":"Duvoix","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.resinv.2025.08.010_bib39","first-page":"359","article-title":"Fibrinogen, COPD and mortality in a nationally representative U.S. cohort","volume":"9","author":"Mannino","year":"2012","journal-title":"COPD J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.08.010_bib40","first-page":"23","article-title":"Plasma fibrinogen as a biomarker for mortality and hospitalized exacerbations in people with COPD","volume":"2","author":"Mannino","year":"2015","journal-title":"Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.08.010_bib41","doi-asserted-by":"crossref","first-page":"181","DOI":"10.2169\/internalmedicine.41.181","article-title":"Elevated plasma procoagulant and fibrinolytic markers in patients with chronic obstructive pulmonary disease","volume":"41","author":"Ashitani","year":"2002","journal-title":"Intern Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib42","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/j.thromres.2011.05.004","article-title":"Thrombin generation in chronic obstructive pulmonary disease: dependence on plasma factor composition","volume":"128","author":"Undas","year":"2011","journal-title":"Thromb Res"},{"key":"10.1016\/j.resinv.2025.08.010_bib43","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s11739-011-0636-1","article-title":"Effect of acute exacerbations on circulating endothelial, clotting and fibrinolytic markers in COPD patients","volume":"8","author":"Polosa","year":"2013","journal-title":"Intern Emerg Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib44","doi-asserted-by":"crossref","first-page":"2729","DOI":"10.2147\/COPD.S112882","article-title":"Prognostic role of D-dimer for in-hospital and 1-year mortality in exacerbations of COPD","volume":"11","author":"Hu","year":"2016","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"10.1016\/j.resinv.2025.08.010_bib45","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1111\/resp.13971","article-title":"Coagulation markers as predictors for clinical events in COPD","volume":"26","author":"Huseb\u00f8","year":"2021","journal-title":"Respirology"},{"key":"10.1016\/j.resinv.2025.08.010_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/0092-8674(80)90526-7","article-title":"Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin)","volume":"19","author":"Grinnell","year":"1980","journal-title":"Cell"},{"key":"10.1016\/j.resinv.2025.08.010_bib47","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/0049-3848(95)00025-9","article-title":"Increased procoagulant and antifibrinolytic activities in the lungs with idiopathic pulmonary fibrosis","volume":"77","author":"Kotani","year":"1995","journal-title":"Thromb Res"},{"key":"10.1016\/j.resinv.2025.08.010_bib48","first-page":"437","article-title":"Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease","volume":"133","author":"Chapman","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1016\/j.resinv.2025.08.010_bib49","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1164\/rccm.200208-905OC","article-title":"Thrombin-activatable fibrinolysis inhibitor and protein C inhibitor in interstitial lung disease","volume":"167","author":"Fujimoto","year":"2003","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib50","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.semarthrit.2010.10.002","article-title":"Coagulation and autoimmunity in scleroderma interstitial lung disease","volume":"41","author":"Ludwicka-Bradley","year":"2011","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.resinv.2025.08.010_bib51","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/s13075-023-03243-z","article-title":"Proteomic profiling identifies SPP1 associated with rapidly progressive interstitial lung disease in anti-MDA5-positive dermatomyositis","volume":"26","author":"Qiu","year":"2024","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.resinv.2025.08.010_bib52","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1164\/ajrccm.163.7.9911068","article-title":"Intratracheal administration of activated protein C inhibits bleomycin-induced lung fibrosis in the mouse","volume":"163","author":"Yasui","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib53","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.2353\/ajpath.2006.050610","article-title":"Thrombin-activatable fibrinolysis inhibitor deficiency attenuates bleomycin-induced lung fibrosis","volume":"168","author":"Fujimoto","year":"2006","journal-title":"Am J Pathol"},{"key":"10.1016\/j.resinv.2025.08.010_bib54","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1056\/NEJM200005043421806","article-title":"The acute respiratory distress syndrome","volume":"342","author":"WareLB","year":"2000","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib55","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1378\/chest.07-2134","article-title":"Mortality rates for patients with acute lung injury\/ARDS have decreased over time","volume":"133","author":"Zambon","year":"2008","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.08.010_bib56","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1056\/NEJMra1608077","article-title":"Acute respiratory distress syndrome","volume":"377","author":"Taylor Thompson","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib57","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.723217","article-title":"Coagulation dysfunction in acute respiratory distress syndrome and its potential impact in inflammatory subphenotypes","volume":"8","author":"Livingstone","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1159\/000453002","article-title":"Immunothrombosis in acute respiratory distress syndrome: cross talks between inflammation and coagulation","volume":"93","author":"Frantzeskaki","year":"2017","journal-title":"Respiration"},{"issue":"3","key":"10.1016\/j.resinv.2025.08.010_bib59","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1378\/chest.128.3.1475","article-title":"Anticoagulant therapy for idiopathic pulmonary fibrosis","volume":"128","author":"Kubo","year":"2005","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.resinv.2025.08.010_bib60","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1164\/rccm.201202-0314OC","article-title":"A placebo controlled randomized trial of warfarin in idiopathic pulmonary fibrosis","volume":"186","author":"Noth","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.resinv.2025.08.010_bib61","first-page":"121","article-title":"The effect of anticoagulant therapy for idiopathic pulmonary fibrosis in real life practice","volume":"30","author":"Tomassetti","year":"2013","journal-title":"al Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"6","key":"10.1016\/j.resinv.2025.08.010_bib62","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1183\/13993003.02087-2015","article-title":"Unfavourable effects of medically indicated oral anticoagulants on survival in idiopathic pulmonary fibrosis","volume":"47","author":"Kreuter","year":"2016","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.resinv.2025.08.010_bib63","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.chest.2020.10.019","article-title":"Association between anticoagulation and survival in interstitial lung disease","volume":"159","author":"Christopher","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.08.010_bib64","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1128\/IAI.67.9.4463-4468.1999","article-title":"Sulfated polysaccharide-directed recruitment of mammalian host proteins: a novel strategy in microbial pathogenesis","volume":"67","author":"Duensing","year":"1999","journal-title":"Infect Immun"},{"key":"10.1016\/j.resinv.2025.08.010_bib65","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/0002-9149(64)90100-6","article-title":"Heparin in the treatment of chronic obstructive bronchopulmonary disease","volume":"14","author":"Boyle","year":"1960","journal-title":"Am J Cardiol"},{"issue":"2","key":"10.1016\/j.resinv.2025.08.010_bib66","first-page":"171","article-title":"Efficacy of low molecular weight heparin in patients with acute exacerbation of chronic obstrauctive pulmonary disease receving ventilator support","volume":"111","author":"Yongbing","year":"2014","journal-title":"COPD J Chronic Obstr Pulm Dis"},{"key":"10.1016\/j.resinv.2025.08.010_bib67","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJM199307083290204","article-title":"Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin","volume":"329","author":"Ahmed","year":"1993","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib68","article-title":"Anti-inflammatory effects of heparin and its derivatives: a systematic review","volume":"2015","author":"Sarah","year":"2015","journal-title":"Adv Pharmacol Sci"},{"issue":"3","key":"10.1016\/j.resinv.2025.08.010_bib69","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1089\/jamp.2009.0780","article-title":"Safety and tolerability of inhaled heparin in idiopathic pulmonary fibrosis","volume":"23","author":"Philipp","year":"2010","journal-title":"J Aerosol Med Pulm Deliv"},{"key":"10.1016\/j.resinv.2025.08.010_bib70","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.1182\/blood-2015-02-355974","article-title":"Activated protein C: biased for translation","volume":"125","author":"Griffin","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2025.08.010_bib71","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJM200103083441001","article-title":"Recombinant human protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis","volume":"344","author":"Bernard","year":"2001","journal-title":"N Engl J Med"},{"issue":"5 Suppl","key":"10.1016\/j.resinv.2025.08.010_bib72","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1097\/01.CCM.0000126122.34119.D1","article-title":"Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C","volume":"32","author":"Yan","year":"2004","journal-title":"Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib73","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib74","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/jth.12841","article-title":"Recombinant human soluble thrombomodulin in severe sepsis: a systematic review and meta-analysis","volume":"13","author":"Yamakawa","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib75","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1517\/14728222.2016.1086750","article-title":"Thrombomodulin as an intravascular safeguard against inflammatory and thrombotic diseases","volume":"20","author":"Ito","year":"2016","journal-title":"Expert Opin Ther Targets"},{"key":"10.1016\/j.resinv.2025.08.010_bib76","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1111\/j.1538-7836.2006.02267.x","article-title":"Efficacy and safety of recombinant human soluble thrombomodulin (ART-123) in disseminated intravascular coagulation: results of a phase III, randomized, double-blind clinical trial","volume":"5","author":"Saito","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib77","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1378\/chest.14-2746","article-title":"Recombinant human thrombomodulin in acute exacerbation of idiopathic pulmonary fibrosis","volume":"148","author":"Kataoka","year":"2015","journal-title":"Chest"},{"key":"10.1016\/j.resinv.2025.08.010_bib78","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1164\/rccm.201909-1818OC","article-title":"Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis: a randomized, double-blind, placebo-controlled trial","volume":"201","author":"Kondoh","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"10.1016\/j.resinv.2025.08.010_bib79","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1164\/rccm.202002-0271LE","article-title":"Too premature to deny the potential of thrombomodulin alfa in idiopathic pulmonary fibrosis","volume":"201","author":"Kobayashi","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.resinv.2025.08.010_bib80","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1164\/rccm.202003-0494LE","article-title":"Thrombomodulin did not benefit acute exacerbation of idiopathic pulmonary fibrosis in a trial","volume":"202","author":"Horita","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib81","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0049-3848(00)00237-1","article-title":"Relevance of tissue factor and tissue factor pathway inhibitor for hypercoagulable state in the lungs of patients with idiopathic pulmonary fibrosis","volume":"99","author":"Fujii","year":"2000","journal-title":"Thromb Res"},{"key":"10.1016\/j.resinv.2025.08.010_bib82","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/00024382-199810000-00005","article-title":"Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock","volume":"10","author":"Goldfarb","year":"1998","journal-title":"Shock"},{"key":"10.1016\/j.resinv.2025.08.010_bib83","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1172\/JCI116529","article-title":"Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock","volume":"91","author":"Creasey","year":"1993","journal-title":"J Clin Investig"},{"key":"10.1016\/j.resinv.2025.08.010_bib84","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1182\/blood.V95.4.1124.002k20_1124_1129","article-title":"Tissue factor pathway inhibitor dose dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia","volume":"95","author":"de Jonge","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2025.08.010_bib85","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1097\/00003246-200111000-00007","article-title":"Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: a multicenter, randomized, placebo-controlled, single-blind, dose escalation study","volume":"29","author":"Abraham","year":"2001","journal-title":"Crit Care Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib86","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1001\/jama.290.2.238","article-title":"Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis: a randomized controlled trial","volume":"290","author":"Abraham","year":"2003","journal-title":"JAMA"},{"key":"10.1016\/j.resinv.2025.08.010_bib87","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1016\/j.drudis.2014.06.024","article-title":"Factor XII: a drug target for safe interference with thrombosis and inflammation","volume":"19","author":"Kenne","year":"2014","journal-title":"Drug Discov Today"},{"issue":"10","key":"10.1016\/j.resinv.2025.08.010_bib88","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1160\/TH16-12-0904","article-title":"Coagulation factor XII regulates inflammatory responses in human lungs","volume":"117","author":"Hess","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.resinv.2025.08.010_bib89","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI anti sense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib90","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1111\/jth.12896","article-title":"Polyphosphate as modulator of hemostasis, thrombosis, and inflammation","volume":"13","author":"Morrissey","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"4","key":"10.1016\/j.resinv.2025.08.010_bib91","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1165\/rcmb.2017-0353OC","article-title":"Secretory inositol polyphosphate 4-phosphatase protects against airway inflammation and remodeling","volume":"60","author":"Khanna","year":"2019","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"9","key":"10.1016\/j.resinv.2025.08.010_bib92","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.16032","article-title":"Plausible role of INPP4A dysregulation in idiopathic pulmonary fibrosis","volume":"12","author":"Arvind","year":"2024","journal-title":"Physiol Rep"},{"key":"10.1016\/j.resinv.2025.08.010_bib93","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nm760","article-title":"Pepducin-based intervention of thrombin-receptor signaling and systemic platelet activation","volume":"8","author":"Covic","year":"2002","journal-title":"Nat Med"},{"key":"10.1016\/j.resinv.2025.08.010_bib94","doi-asserted-by":"crossref","first-page":"3176","DOI":"10.1182\/blood-2007-02-075440","article-title":"Protease-activated receptor-4 inhibition protects from multiorgan failure in a murine model of systemic inflammation","volume":"110","author":"Slofstra","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.resinv.2025.08.010_bib95","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.blre.2014.10.006","article-title":"Approval of the first protease-activated receptor antagonist: rationale, development, significance, and considerations of a novel anti-platelet agent","volume":"29","author":"French","year":"2015","journal-title":"Blood Rev"},{"key":"10.1016\/j.resinv.2025.08.010_bib96","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/jcbfm.2009.283","article-title":"Deficiency of PAR4 attenuates cerebral ischemia\/reperfusion injury in mice","volume":"30","author":"Mao","year":"2010","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.resinv.2025.08.010_bib97","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1124\/jpet.109.162602","article-title":"Parstatin(1-26): the putative signal peptide of protease-activated receptor 1 confers potent protection from myocardial ischemia reperfusion injury","volume":"332","author":"Routhu","year":"2010","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Respiratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2212534525001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T15:48:01Z","timestamp":1772898481000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2212534525001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":97,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S2212534525001340"],"URL":"https:\/\/doi.org\/10.1016\/j.resinv.2025.08.010","relation":{},"ISSN":["2212-5345"],"issn-type":[{"value":"2212-5345","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The role of the coagulation-fibrinolysis system in airway and lung remodeling","name":"articletitle","label":"Article Title"},{"value":"Respiratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.resinv.2025.08.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Japanese Respiratory Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}